- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02769065
Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants
A Phase 1 Safety, Tolerability, and Pharmacokinetic Study of Escalating Single and Multiple Oral Doses of TAK-071 in Healthy Subjects and Subjects With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability and Food Effect of TAK-071 in Healthy Subjects
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
TAK-071 was being tested to find a safe and well-tolerated dose in healthy participants (non-Japanese and Japanese) and participants with MCI or mild AD (non-Japanese).
The study enrolled 179 participants. The study consisted of 4 parts: Single-rising dose (SRD) part (Cohorts 1-6, and 18-22), multiple-rising dose (MRD) part (Cohorts 7-15), Cohort 16 with 2-arm parallel design, and Cohort 17 relative bioavailability and food effect 3 period crossover design.
Participants in each cohort were randomized to receive treatment with TAK-071 or matching placebo using drug-in-capsule (DIC) in the morning following a minimum fast of 8 hours. In Cohort 16, participants were assigned to 1 of 2 possible treatments, TAK-071 or matching placebo. In Cohort 17, participants were assigned to 1 of 3 treatment sequences (ABC, BCA, or CAB) with treatment A being fasted state and capsule formulation, treatment B being fasted state and tablet formulation, and treatment C being fed state and tablet formulation. In Cohorts 20-22, participants were administered as a single dose of TAK-071 or placebo on Day 1, and a single dose of donepezil or placebo approximately 24 hours later on Day 2.
This multi-center trial was conducted in United States. The overall time to participate in this study was approximately 41 days. Participants made multiple visits to the clinic and were also contacted for the follow-up through the telephone.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Glendale, California, United States
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Man or woman who weighs at least 50 kg and has a body mass index (BMI) from 18.0 to 30.0 kg/m^2, inclusive, at Screening. Participants should be aged 18 to 55 years, inclusive (nonelderly at the time of informed consent and first study drug dose) for Cohorts 1 to 12, and 17 to 22; 20 to 55 years, inclusive, for Cohorts 13 to 15; and 55 to 90 years, inclusive, for participants in Cohort 16.
- For Cohorts 13 to 15 only: First-generation Japanese, defined as having been born in Japan of Japanese parents and Japanese grandparents and living no more than 10 years outside of Japan, with no significant change in lifestyle, including diet, while living outside of Japan.
- Cohort 16 only: Healthy elderly or participants with MCI or mild AD, who must have Mini Mental State Examination (MMSE) score of 18 to 30, inclusive or 18 to 26 inclusive, respectively, and no biomarker data to contradict this diagnosis. Participants with documented diagnosis of MCI or mild AD must be receiving ongoing donepezil therapy (10 mg) in the evening for a minimum of 21 days prior to Check-in (Day -1) or must consent to take donepezil dose titrated to at least 21 days of treatment with 10 mg QD prior to Check-in.
Exclusion Criteria:
- Has clinically significant (Cohorts 1 to 15 and 17 to 22) or uncontrolled (Cohort 16) neurologic, cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal (GI), urologic, immunologic, endocrine, or psychiatric disease or other abnormality (other than the disease being studied), which may impact the ability of the participant to participate or potentially confound the study results.
- Has a history of type 1 diabetes (Cohorts 1 to 22) or type 2 diabetes (Cohorts 1 to 15, 17 to 22) or hemoglobin A1c >6.5% at Screening. Note: participants with controlled (hemoglobin A1c <7.0% at Screening) type 2 diabetes in Cohort 16 may participate in the study.
- Has a risk of suicide or suicidal ideation with intent and plan according to the investigator's clinical judgment (affirmative answer to questions 4 and 5 of the ideation section of the Columbia-Suicide Severity Rating Scale) or has made a suicide attempt in the previous 6 months.
- Cohort 16 only: Any significant neurologic disease (other than suspected incipient or mild AD), such as Parkinson disease, stroke, transient ischemic attack, multi-infarct dementia, Huntington disease, head trauma with clinically significant cognitive sequelae, or chronic central nervous system infection, per investigator discretion.
- Has current or recent (within 6 months) GI disease that would be expected to influence the absorption of drugs (ie, a history of malabsorption, any surgical intervention known to impact absorption [eg, bariatric surgery or bowel resection], esophageal reflux, peptic ulcer disease, erosive esophagitis, or frequent [more than once per week] occurrence of heartburn).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: SRD: Placebo Cohorts 1-6, 18 and 19
TAK-071 placebo-matching capsules, orally, once on Day 1 to non-Japanese healthy participants in the single-rising dose (SRD) period.
|
TAK-071 placebo-matching capsules
|
Experimental: SRD: Cohort 1: TAK-071 1 mg
TAK-071 1 mg, capsule, orally, once on Day 1 to non-Japanese healthy participants.
|
TAK-071 capsules
|
Experimental: SRD: Cohort 2: TAK-071 3 mg
TAK-071 3 mg capsule, orally, once on Day 1 to non-Japanese healthy participants.
Dose of TAK-071 was based on the 24-hour post-dose safety, tolerability and pharmacokinetic (PK) data from cohort 1.
|
TAK-071 capsules
|
Experimental: SRD: Cohort 3: TAK-071 9 mg
TAK-071 9 mg capsule, orally, once on Day 1 to non-Japanese healthy participants.
Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK and 12-hour CSF PK data.
|
TAK-071 capsules
|
Experimental: SRD: Cohort 4: TAK-071 20 mg
TAK-071 20 mg capsule, orally, once on Day 1 to non-Japanese healthy participants.
Dose of TAK-071 was based on the 24-hour post-dose safety and tolerability data from previous cohort.
|
TAK-071 capsules
|
Experimental: SRD: Cohort 5: TAK-071 40 mg
TAK-071 40 mg capsule, orally, once on Day 1 to non-Japanese healthy participants.
Dose of TAK-071 will be based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 4.
|
TAK-071 capsules
|
Experimental: SRD: Cohort 6: TAK-071 80 mg
TAK-071 80 mg capsules, orally, once on Day 1 to non-Japanese healthy participants.
Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 5
|
TAK-071 capsules
|
Placebo Comparator: MRD: Placebo Cohorts 7-9
TAK-071 placebo-matching capsule, orally, once on Day 1 to non-Japanese healthy participants in the multiple-rising dose (MRD) period.
|
TAK-071 placebo-matching capsules
|
Experimental: MRD: Cohort 7: TAK-071 3 mg
TAK-071 3 mg capsules, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants.
Dose of TAK-071 was based on 24-hour safety and tolerability from Cohort 4 and the 24-hour preliminary plasma PK and 12-hour CSF PK data from Cohort 3.
|
TAK-071 capsules
|
Experimental: MRD: Cohort 8: TAK-071 9 mg
TAK-071 9 mg capsules, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants.
Dose of TAK-071 was based on safety, tolerability and available PK data arising from the ongoing SRD part and previous MRD cohort.
|
TAK-071 capsules
|
Experimental: MRD: Cohort 9: TAK-071 15 mg
TAK-071 15 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to non-Japanese healthy participants.
Dose of TAK-071 will be based on safety, tolerability and available PK data arising from the ongoing SRD part and previous MRD cohort.
|
TAK-071 capsules
|
Placebo Comparator: MRD: TAK-071 Placebo Cohorts 10-12+Donepezil
TAK-071 placebo-matching capsule, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071.
|
TAK-071 placebo-matching capsules
Donepezil over-encapsulated tablet
|
Experimental: MRD: Cohort 10: TAK-071 3 mg+Donepezil 5 mg
TAK-071 3 mg capsules, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071.
Dose of TAK-071 was same as the dose used in MRD Cohort 7.
|
TAK-071 capsules
Donepezil over-encapsulated tablet
|
Experimental: MRD: Cohort 11: TAK-071 9 mg + Donepezil 5 mg
TAK-071 9 mg capsules, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071.
Dose of TAK-071 was same as the dose used in MRD Cohort 8.
|
TAK-071 capsules
Donepezil over-encapsulated tablet
|
Experimental: MRD: Cohort 12: TAK-071 15 mg+Donepezil 5 mg
TAK-071 15 mg capsule, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071.
Dose of TAK-071 was same as the dose used in MRD Cohort 9.
|
TAK-071 capsules
Donepezil over-encapsulated tablet
|
Experimental: MRD: Placebo Cohorts 13-15
TAK-071 placebo-matching capsule, orally, once on Day 1 to Japanese healthy participants.
|
TAK-071 placebo-matching capsules
|
Experimental: MRD: Cohort 13: TAK-071 3 mg
TAK-071 3 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants.
Dose of TAK-071 was same as the dose used in MRD Cohort 7.
|
TAK-071 capsules
|
Experimental: MRD: Cohort 14: TAK-071 9 mg
TAK-071 9 mg capsule or matching placebo, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants.
Dose of TAK-071 was same as the dose used in MRD Cohort 8.
|
TAK-071 capsules
|
Experimental: MRD: Cohort 15: TAK-071 15 mg
TAK-071 15 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants.
Dose of TAK-071 was same as the dose used in MRD Cohort 9.
|
TAK-071 capsules
|
Experimental: Cohort 16
|
TAK-071 capsules
|
Experimental: Bioavailability (BA)/Food Effect: Cohort 17 Sequence ABC
A: TAK-071 10 mg capsule, orally once on Day 1 in the fasted state in Period 1, followed by B: TAK-071 10 mg tablet, orally, once on Day 1 in the fasted state in Period 2, followed by C: TAK-071 10 mg tablet, orally, once on Day 1 in the fed state in Period 3 in non-Japanese healthy participants.
There was a 21-day washout after each period.
|
TAK-071 capsules
|
Experimental: BA/Food Effect: Cohort 17 Sequence BCA
B: TAK-071 10 mg tablet, orally, once on Day 1 in the fasted state in Period 1, followed by C: TAK-071 10 mg tablet, orally, once on Day 1 in the Fed state in Period 2, followed by A: TAK-071 10 mg capsule, orally once on Day 1 in the fasted state Period 3 in non-Japanese healthy participants.
There was a 21-day washout after each period.
|
TAK-071 capsules
|
Experimental: BA/Food Effect: Cohort 17 Sequence CAB
C: TAK-071 10 mg tablet, orally, once on Day 1 in the fed state in Period 1, followed by A: TAK-071 10 mg capsule, orally once on Day 1 in the fasted state in Period 2, followed by B: TAK-20 10 mg tablet, orally, once on Day 1 in the fasted state in Period 3 in non-Japanese healthy participants.
There was a 21-day washout after each period.
|
TAK-071 capsules
|
Experimental: SRD: Cohort 18: TAK-071 120 mg
TAK-071 120 mg capsule, orally, once on Day 1 to non-Japanese healthy participants.
Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 6.
|
TAK-071 capsules
|
Experimental: SRD: Cohort 19: TAK-071 160 mg
TAK-071 160 mg capsule, orally, once on Day 1 to non-Japanese healthy participants.
Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 18.
|
TAK-071 capsules
|
Placebo Comparator: SRD: TAK-071 Placebo+Donepezil Placebo
TAK-071 placebo-matching capsule, orally, once on Day 1 followed by donepezil placebo-matching tablet, orally on Day 2 to non-Japanese healthy participants.
|
TAK-071 placebo-matching capsules
Donepezil placebo-matching over-encapsulated tablet
|
Placebo Comparator: SRD: TAK-071 Placebo+Donepezil
TAK-071 placebo-matching capsule, orally, once on Day 1 followed by donepezil 10 mg tablet, orally, on Day 2 to non-Japanese healthy participants.
|
TAK-071 placebo-matching capsules
Donepezil over-encapsulated tablet
|
Experimental: SRD: Cohort 20: TAK-071 40 mg+Donepezil
TAK-071 40 mg capsule, orally, once on Day 1 followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants.
Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 19.
|
TAK-071 capsules
Donepezil over-encapsulated tablet
|
Experimental: SRD: Cohort 21: TAK-071 60 mg+Donepezil
TAK-071 60 mg capsule, orally, once on Day 1 followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants.
Dose of TAK-071 was based on 24-hour safety and tolerability data from Cohort 20.
|
TAK-071 capsules
Donepezil over-encapsulated tablet
|
Experimental: SRD: Cohort 22: TAK-071 80 mg+Donepizil
TAK-071 80 mg capsule, orally, once on Day 1, followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants.
Dose of TAK-071 was based on 24-hour safety and tolerability data from Cohort 21.
|
TAK-071 capsules
Donepezil over-encapsulated tablet
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants Who Experienced at Least One Treatment-Emergent Adverse Event (TEAE)
Time Frame: Day 1 up to Day 41
|
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment.
A TEAE is defined as an adverse event with an onset that occurs or gets worse after receiving study drug.
|
Day 1 up to Day 41
|
Percentage of Participants Who Meet the Markedly Abnormal Criteria for Clinical Laboratory Tests at Least Once Post-dose
Time Frame: Day 1 up to Day 41
|
Clinical laboratory tests included serum chemistry, hematology, coagulation and urinalysis.
ULN=upper limit of normal range.
|
Day 1 up to Day 41
|
Percentage of Participants Who Meet the Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Post-dose
Time Frame: Day 1 up to Day 41
|
Vital Sign measurements included systolic blood pressure (SBP), diastolic blood presssure (DBP), pulse, temperature, orthostatic SBP, orthostatic DBP and orthostatic pulse.
|
Day 1 up to Day 41
|
Percentage of Participants Who Meet the Markedly Abnormal Criteria for 12-lead Electrocardiogram (ECG) Parameters at Least Once Post-dose
Time Frame: Day 1 up to Day 41
|
A standard 12-lead electrocardiogram (ECG) was performed.
The percentage of participants with markedly abnormal ECG findings during the study.
|
Day 1 up to Day 41
|
Tmax: Time of First Occurrence of Cmax for TAK-071 Single-Rising Dose (SRD) Non-Japanese Participants
Time Frame: Pre-dose on Day 1 and at multiple time points (up to 168 hours) post-dose
|
Pre-dose on Day 1 and at multiple time points (up to 168 hours) post-dose
|
|
Tmax: Time of First Occurrence of Cmax for TAK-071 Multiple-Rising Dose (MRD) Non-Japanese Participants [Day 1]
Time Frame: Pre-dose on Day 1 and multiple time points (up to 24 hours) post-dose
|
Pre-dose on Day 1 and multiple time points (up to 24 hours) post-dose
|
|
Tmax: Time of First Occurrence of Cmax for TAK-071 MRD Non-Japanese Participants [Day 21]
Time Frame: Pre-dose on Day 21 and multiple time points (up to 24 hours) post-dose
|
Pre-dose on Day 21 and multiple time points (up to 24 hours) post-dose
|
|
Tmax: Time of First Occurrence of Cmax for TAK-071 MRD Non-Japanese Participants [Day 1]
Time Frame: Pre-dose on Day 1 and multiple time points (up to 96 hours) post-dose
|
Pre-dose on Day 1 and multiple time points (up to 96 hours) post-dose
|
|
Tmax: Time of First Occurrence of Cmax for TAK-071 MRD Non-Japanese Participants [Day 8]
Time Frame: Pre-dose on Day 8 and multiple time points (up to 24 hour) post-dose
|
Pre-dose on Day 8 and multiple time points (up to 24 hour) post-dose
|
|
Tmax: Time of First Occurrence of Cmax for TAK-071 MRD Non-Japanese Participants [Day 28]
Time Frame: Pre-dose on Day 28 and multiple time points (up to 36 hours) post-dose
|
Pre-dose on Day 28 and multiple time points (up to 36 hours) post-dose
|
|
Tmax: Time of First Occurrence of Cmax for TAK-071 MRD Japanese Participants [Day 1]
Time Frame: Pre-dose on Day 1 and multiple time points (up to 96 hours) post-dose
|
Pre-dose on Day 1 and multiple time points (up to 96 hours) post-dose
|
|
Tmax: Time of First Occurrence of Cmax for TAK-071 MRD Japanese Participants [Day 8]
Time Frame: Pre-dose on Day 8 and multiple time points (up to 24 hours) post-dose
|
Pre-dose on Day 8 and multiple time points (up to 24 hours) post-dose
|
|
Tmax: Time of First Occurrence of Cmax for TAK-071 MRD Japanese Participants [Day 28]
Time Frame: Pre-dose on Day 28 and multiple time points (up to 24 hours) post-dose
|
Pre-dose on Day 28 and multiple time points (up to 24 hours) post-dose
|
|
Tmax: Time of First Occurrence of Cmax for TAK-071 MRD Non-Japanese Participants [Day 1]
Time Frame: Pre-dose on Day 1 and multiple time points (up to 24 hours) post-dose
|
Pre-dose on Day 1 and multiple time points (up to 24 hours) post-dose
|
|
Tmax: Time of First Occurrence of Cmax for TAK-071 Relative Bioavailability and Food Effect
Time Frame: Pre-dose on Day 21 and multiple time points (up to 168 hours) post-dose
|
Pre-dose on Day 21 and multiple time points (up to 168 hours) post-dose
|
|
Tmax: Time of First Occurrence of Cmax for TAK-071 SRD Non-Japanese Participants TAK-071+Donepezil
Time Frame: Pre-dose on Day 1 and at multiple time points (up to 168 hours) post-dose
|
Pre-dose on Day 1 and at multiple time points (up to 168 hours) post-dose
|
|
Cmax: Maximum Observed Plasma Concentration for TAK-071 Single-Rising Dose (SRD) Non-Japanese Participants
Time Frame: Pre-dose on Day 1 and at multiple time points (up to 168 hours) post-dose
|
Pre-dose on Day 1 and at multiple time points (up to 168 hours) post-dose
|
|
Cmax: Maximum Observed Plasma Concentration for TAK-071 Multiple-Rising Dose (MRD) Non-Japanese Participants [Day 1]
Time Frame: Pre-dose on Day 1 and multiple time points (up to 24 hours) post-dose
|
Pre-dose on Day 1 and multiple time points (up to 24 hours) post-dose
|
|
Cmax: Maximum Observed Plasma Concentration for TAK-071 MRD Non-Japanese Participants [Day 21]
Time Frame: Pre-dose on Day 21 and multiple time points (up to 24 hours) post-dose
|
Pre-dose on Day 21 and multiple time points (up to 24 hours) post-dose
|
|
Cmax: Maximum Observed Plasma Concentration for TAK-071 MRD Non-Japanese Participants [Day 1]
Time Frame: Pre-dose on Day 1 and multiple time points (up to 96 hours) post-dose
|
Pre-dose on Day 1 and multiple time points (up to 96 hours) post-dose
|
|
Cmax: Maximum Observed Plasma Concentration for TAK-071 MRD Non-Japanese Participants [Day 8]
Time Frame: Pre-dose on Day 8 and multiple time points (up to 24 hour) post-dose
|
Pre-dose on Day 8 and multiple time points (up to 24 hour) post-dose
|
|
Cmax: Maximum Observed Plasma Concentration for TAK-071 MRD Non-Japanese Participants [Day 28]
Time Frame: Pre-dose on Day 28 and multiple time points (up to 36 hours) post-dose
|
Pre-dose on Day 28 and multiple time points (up to 36 hours) post-dose
|
|
Cmax: Maximum Observed Plasma Concentration for TAK-071 MRD Japanese Participants [Day 1]
Time Frame: Pre-dose on Day 1 and multiple time points (up to 96 hours) post-dose
|
Pre-dose on Day 1 and multiple time points (up to 96 hours) post-dose
|
|
Cmax: Maximum Observed Plasma Concentration for TAK-071 MRD Japanese Participants [Day 8]
Time Frame: Pre-dose on Day 8 and multiple time points (up to 24 hours) post-dose
|
Pre-dose on Day 8 and multiple time points (up to 24 hours) post-dose
|
|
Cmax: Maximum Observed Plasma Concentration for TAK-071 MRD Japanese Participants [Day 28]
Time Frame: Pre-dose on Day 28 and multiple time points (up to 24 hours) post-dose
|
Pre-dose on Day 28 and multiple time points (up to 24 hours) post-dose
|
|
Cmax: Maximum Observed Plasma Concentration for TAK-071 MRD Non-Japanese Participants [Day 1]
Time Frame: Pre-dose on Day 1 and multiple time points (up to 24 hours) post-dose
|
Pre-dose on Day 1 and multiple time points (up to 24 hours) post-dose
|
|
Cmax: Maximum Observed Plasma Concentration for TAK-071 Relative Bioavailability and Food Effect
Time Frame: Pre-dose on Day 1 and multiple time points (up to 168 hours) post-dose
|
Pre-dose on Day 1 and multiple time points (up to 168 hours) post-dose
|
|
Cmax: Maximum Observed Plasma Concentration for TAK-071 SRD Non-Japanese Participants TAK-071+Donepezil
Time Frame: Pre-dose on Day 1 and at multiple time points (up to 168 hours) post-dose
|
Pre-dose on Day 1 and at multiple time points (up to 168 hours) post-dose
|
|
AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours for TAK-071 Single-Rising Dose (SRD) Non-Japanese Participants
Time Frame: Pre-dose on Day 1 and at multiple time points (up to 168 hours) post-dose
|
Pre-dose on Day 1 and at multiple time points (up to 168 hours) post-dose
|
|
AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours for TAK-071 Multiple-Rising Dose (MRD) Non-Japanese Participants [Day 1]
Time Frame: Pre-dose on Day 1 and multiple time points (up to 24 hours) post-dose
|
Pre-dose on Day 1 and multiple time points (up to 24 hours) post-dose
|
|
AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours for TAK-071 MRD Non-Japanese Participants [Day 21]
Time Frame: Pre-dose on Day 21 and multiple time points (up to 24 hours) post-dose
|
Pre-dose on Day 21 and multiple time points (up to 24 hours) post-dose
|
|
AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours for TAK-071 MRD Non-Japanese Participants [Day 1]
Time Frame: Pre-dose on Day 1 and multiple time points (up to 96 hours) post-dose
|
Pre-dose on Day 1 and multiple time points (up to 96 hours) post-dose
|
|
AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours for TAK-071 MRD Non-Japanese Participants [Day 8]
Time Frame: Pre-dose on Day 8 and multiple time points (up to 24 hour) post-dose
|
Pre-dose on Day 8 and multiple time points (up to 24 hour) post-dose
|
|
AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours for TAK-071 MRD Non-Japanese Participants [Day 28]
Time Frame: Pre-dose on Day 28 and multiple time points (up to 36 hours) post-dose
|
Pre-dose on Day 28 and multiple time points (up to 36 hours) post-dose
|
|
AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours for TAK-071 MRD Japanese Participants [Day 1]
Time Frame: Pre-dose on Day 1 and multiple time points (up to 96 hours) post-dose
|
Pre-dose on Day 1 and multiple time points (up to 96 hours) post-dose
|
|
AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours for TAK-071 MRD Japanese Participants [Day 8]
Time Frame: Pre-dose on Day 8 and multiple time points (up to 24 hours) post-dose
|
Pre-dose on Day 8 and multiple time points (up to 24 hours) post-dose
|
|
AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours for TAK-071 MRD Japanese Participants [Day 28]
Time Frame: Pre-dose on Day 28 and multiple time points (up to 24 hours) post-dose
|
Pre-dose on Day 28 and multiple time points (up to 24 hours) post-dose
|
|
AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours for TAK-071 MRD Non-Japanese Participants [Day 1]
Time Frame: Pre-dose on Day 1 and multiple time points (up to 24 hours) post-dose
|
Pre-dose on Day 1 and multiple time points (up to 24 hours) post-dose
|
|
AUC∞: Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity for TAK-071 Relative Bioavailability and Food Effect
Time Frame: Pre-dose on Day 21 and multiple time points (up to 168 hours) post-dose
|
Pre-dose on Day 21 and multiple time points (up to 168 hours) post-dose
|
|
AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours for TAK-071 SRD Non-Japanese Participants TAK-071+Donepezil
Time Frame: Pre-dose on Day 1 and at multiple time points (up to 168 hours) post-dose
|
Pre-dose on Day 1 and at multiple time points (up to 168 hours) post-dose
|
|
AUC∞: Area Under the Concentration-Time Curve From Time 0 to Infinity, Calculated Using the Observed Value of the Last Quantifiable Concentration for TAK-071 SRD Non-Japanese Participants
Time Frame: Pre-dose on Day 1 and at multiple time points [up to 168 hours] post-dose
|
Pre-dose on Day 1 and at multiple time points [up to 168 hours] post-dose
|
|
AUC∞: Area Under the Concentration-Time Curve From Time 0 to Infinity, Calculated Using the Observed Value of the Last Quantifiable Concentration for TAK-071 SRD Non-Japanese Participants TAK-071 + Donepezil
Time Frame: Pre-dose on Day 1 and at multiple time points [up to 168 hours] post-dose
|
Pre-dose on Day 1 and at multiple time points [up to 168 hours] post-dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AUClast: Area Under the Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration for TAK-071 MRD Non-Japanese Participants
Time Frame: Pre-dose on Day 1 and at multiple time points (up to 168 hours) post-dose
|
Pre-dose on Day 1 and at multiple time points (up to 168 hours) post-dose
|
|
AUClast: Area Under the Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration for TAK-071 MRD Non-Japanese Participants
Time Frame: Pre-dose on Day 1 and multiple timepoints (up to 24 hrs) post-dose for Cohorts 7 and 8 and Pre-dose on Day 1 and multiple timepoints (up to 96 hrs) post-dose for Cohort 9
|
Pre-dose on Day 1 and multiple timepoints (up to 24 hrs) post-dose for Cohorts 7 and 8 and Pre-dose on Day 1 and multiple timepoints (up to 96 hrs) post-dose for Cohort 9
|
|
AUClast: Area Under the Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration for TAK-071 MRD Japanese Participants
Time Frame: Pre-dose on Day 1 and multiple time points (up to 96 hours) post-dose and Pre-dose on Day 8 and multiple time points (up to 24 hours) post-dose
|
Pre-dose on Day 1 and multiple time points (up to 96 hours) post-dose and Pre-dose on Day 8 and multiple time points (up to 24 hours) post-dose
|
|
AUClast: Area Under the Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration for TAK-071 MRD Non-Japanese
Time Frame: Pre-dose on Day 1 and at multiple time points (up to 24 hours) post-dose
|
Pre-dose on Day 1 and at multiple time points (up to 24 hours) post-dose
|
|
AUClast: Area Under the Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration for TAK-071 Relative Bioavailability and Food Effect
Time Frame: Pre-dose on Day 1 and multiple time points (up to 168 hours) post-dose
|
Pre-dose on Day 1 and multiple time points (up to 168 hours) post-dose
|
|
AUClast: Area Under the Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration for TAK-071 SRD Non-Japanese Participants TAK-071+Donepezil
Time Frame: Pre-dose on Day 1 and multiple time points (up to 168 hours) post-dose
|
Pre-dose on Day 1 and multiple time points (up to 168 hours) post-dose
|
|
Terminal Disposition Phase Half-life (t1/2z) for TAK-071 SRD Non-Japanese Participants
Time Frame: Pre-dose on Day 1 and at multiple time points (up to 168 hours) post-dose
|
Pre-dose on Day 1 and at multiple time points (up to 168 hours) post-dose
|
|
Terminal Disposition Phase Half-life (t1/2z) for TAK-071 Relative Bioavailability and Food Effect
Time Frame: Pre-dose on Day 21 and multiple time points (up to 168 hours) post-dose
|
Pre-dose on Day 21 and multiple time points (up to 168 hours) post-dose
|
|
Terminal Disposition Phase Half-life (t1/2z) for TAK-071 SRD Non-Japanese Participants TAK-071+Donepezil
Time Frame: Pre-dose on Day 1 and multiple time points (up to 168 hours) post-dose
|
Pre-dose on Day 1 and multiple time points (up to 168 hours) post-dose
|
|
CL/F: Apparent Clearance After Extravascular Administration for TAK-071 SRD Non-Japanese Participants
Time Frame: Pre-dose on Day 1 and at multiple time points (up to 168 hours) post-dose
|
Pre-dose on Day 1 and at multiple time points (up to 168 hours) post-dose
|
|
CL/F: Apparent Clearance After Extravascular Administration for TAK-071 Relative Bioavailability and Food Effect
Time Frame: Pre-dose on Day 21 and multiple time points (up to 168 hours) post-dose
|
Pre-dose on Day 21 and multiple time points (up to 168 hours) post-dose
|
|
CL/F: Apparent Clearance After Extravascular Administration for TAK-071 SRD Non-Japanese Participants TAK-071+Donepezil
Time Frame: Pre-dose on Day 1 and at multiple time points (up to 168 hours) post-dose
|
Pre-dose on Day 1 and at multiple time points (up to 168 hours) post-dose
|
|
Vz/F: Apparent Volume of Distribution During the Terminal Disposition Phase After Extravascular Administration for TAK-071 SRD Non-Japanese Participants
Time Frame: Pre-dose on Day 1 and at multiple time points (up to 168 hours) post-dose
|
Pre-dose on Day 1 and at multiple time points (up to 168 hours) post-dose
|
|
Vz/F: Apparent Volume of Distribution During the Terminal Disposition Phase After Extravascular Administration for TAK-071 Relative Bioavailability and Food Effect
Time Frame: Pre-dose on Day 21 and multiple time points (up to 168 hours) post-dose
|
Pre-dose on Day 21 and multiple time points (up to 168 hours) post-dose
|
|
Vz/F: Apparent Volume of Distribution During the Terminal Disposition Phase After Extravascular Administration for TAK-071 SRD Non-Japanese Participants TAK-071 + Donepezil
Time Frame: Pre-dose on Day 1 and at multiple time points (up to 168 hours) post-dose
|
Pre-dose on Day 1 and at multiple time points (up to 168 hours) post-dose
|
|
Accumulation Ratio Based on AUCτ (Rac[AUC]) for TAK-071 MRD Non-Japanese Participants
Time Frame: Pre-dose on Day 21 and at multiple time points (up to 24 hours) post-dose for Cohorts 7 and 8 and Pre-dose on Day 28 and at multiple time points (up to 36 hours) post-dose for Cohort 9
|
Pre-dose on Day 21 and at multiple time points (up to 24 hours) post-dose for Cohorts 7 and 8 and Pre-dose on Day 28 and at multiple time points (up to 36 hours) post-dose for Cohort 9
|
|
Accumulation Ratio Based on AUCτ (Rac[AUC]) for TAK-071 MRD Japanese Participants
Time Frame: Pre-dose on Day 28 and at multiple time points [up to 24 hours] post-dose
|
Pre-dose on Day 28 and at multiple time points [up to 24 hours] post-dose
|
|
Accumulation Ratio Based on AUCτ (Rac[AUC]) for TAK-071 MRD Non-Japanese Participants
Time Frame: Pre-dose on Day 21 and at multiple time points [up to 24 hours] post-dose
|
Pre-dose on Day 21 and at multiple time points [up to 24 hours] post-dose
|
|
Accumulation Ratio Based on Plasma Cmax (Rac[Cmax]) for TAK-071 MRD Non-Japanese Participants
Time Frame: Pre-dose on Day 21 and at multiple time points [up to 24 hours] post-dose for Cohorts 7 and 8 and Pre-dose on Day 28 and at multiple time points (up to 36 hours) post-dose for Cohort 9
|
Pre-dose on Day 21 and at multiple time points [up to 24 hours] post-dose for Cohorts 7 and 8 and Pre-dose on Day 28 and at multiple time points (up to 36 hours) post-dose for Cohort 9
|
|
Accumulation Ratio Based on Plasma Cmax (Rac[Cmax]) for TAK-071 MRD Japanese Participants
Time Frame: Pre-dose on Day 28 and at multiple time points [up to 24 hours] post-dose
|
Pre-dose on Day 28 and at multiple time points [up to 24 hours] post-dose
|
|
Accumulation Ratio Based on Plasma Cmax (Rac[Cmax]) for TAK-071 MRD Non-Japanese Participants
Time Frame: Pre-dose on Day 21 and at multiple time points [up to 24 hours] post-dose
|
Pre-dose on Day 21 and at multiple time points [up to 24 hours] post-dose
|
|
AEt: Amount of Drug Excreted in Urine From Time 0 to Time t for TAK-071 SRD Non-Japanese Participants
Time Frame: Pre-dose on Day 1 and at multiple time points [up to 96 hours] post-dose
|
Pre-dose on Day 1 and at multiple time points [up to 96 hours] post-dose
|
|
AEt: Amount of Drug Excreted in Urine From Time 0 to Time t for TAK-071 MRD Non-Japanese Participants
Time Frame: Pre-dose on Day 1 and 21 and at multiple time points (up to 24 hours) post-dose for Cohorts 7 and 8, and pre-dose on Day 1 and 28 and multiple time points (up to 96 hours) post-dose for Cohort 9
|
Pre-dose on Day 1 and 21 and at multiple time points (up to 24 hours) post-dose for Cohorts 7 and 8, and pre-dose on Day 1 and 28 and multiple time points (up to 96 hours) post-dose for Cohort 9
|
|
AEt: Amount of Drug Excreted in Urine From Time 0 to Time t for TAK-071 MRD Japanese Participants
Time Frame: Pre-dose on Day 1 and at multiple time points (up to 96 hours) post-dose and pre-dose on Day 28 and multiple time points (up to 24 hours) post-dose
|
Pre-dose on Day 1 and at multiple time points (up to 96 hours) post-dose and pre-dose on Day 28 and multiple time points (up to 24 hours) post-dose
|
|
Fet: Fraction of Administered Dose of Drug Excreted in Urine From Time 0 to Time t for TAK-071 SRD Non-Japanese Participants
Time Frame: Pre-dose on Day 1 and at multiple time points (up to 96 hours) post-dose
|
Pre-dose on Day 1 and at multiple time points (up to 96 hours) post-dose
|
|
Fet: Fraction of Administered Dose of Drug Excreted in Urine From Time 0 to Time t for TAK-071 MRD Non-Japanese Participants
Time Frame: Pre-dose on Days 1 and 21 and at multiple time points (up to 24 hours) post-dose for Cohorts 7 and 8 and Pre-dose on Days 1 and 28 and multiple time points (up to 96 hours) post-dose for Cohort 9
|
Pre-dose on Days 1 and 21 and at multiple time points (up to 24 hours) post-dose for Cohorts 7 and 8 and Pre-dose on Days 1 and 28 and multiple time points (up to 96 hours) post-dose for Cohort 9
|
|
Fet: Fraction of Administered Dose of Drug Excreted in Urine From Time 0 to Time t for TAK-071 MRD Japanese Participants
Time Frame: Pre-dose on Day 1 and at multiple time points (up to 96 hours) post-dose and pre-dose on Day 28 and multiple time points (up to 24 hours) post-dose
|
Pre-dose on Day 1 and at multiple time points (up to 96 hours) post-dose and pre-dose on Day 28 and multiple time points (up to 24 hours) post-dose
|
|
CLR: Renal Clearance for TAK-071 SRD Non-Japanese Participants
Time Frame: Pre-dose on Day 1 and at multiple time points [up to 96 hours] post-dose
|
Pre-dose on Day 1 and at multiple time points [up to 96 hours] post-dose
|
|
CLR: Renal Clearance for TAK-071 MRD Non-Japanese Participants
Time Frame: Pre-dose on Days 1 and 21 and at multiple time points (up to 24 hours) post-dose for Cohorts 7 and 8 and Pre-dose on Days 1 and 28 multiple time points (up to 96 hours) post-dose for Cohort 9
|
Pre-dose on Days 1 and 21 and at multiple time points (up to 24 hours) post-dose for Cohorts 7 and 8 and Pre-dose on Days 1 and 28 multiple time points (up to 96 hours) post-dose for Cohort 9
|
|
CLR: Renal Clearance for TAK-071 MRD Japanese Participants
Time Frame: Pre-dose on Day 1 and at multiple time points (up to 96 hours) post-dose and pre-dose on Day 28 and multiple time points (up to 24 hours) post-dose
|
Pre-dose on Day 1 and at multiple time points (up to 96 hours) post-dose and pre-dose on Day 28 and multiple time points (up to 24 hours) post-dose
|
|
CSF Cmax: Maximum Observed Concentration in Cerebrospinal Fluid (CSF) for TAK-071
Time Frame: Pre-dose on Day 1 and at multiple time points (up to 12 hours) post-dose
|
Pre-dose on Day 1 and at multiple time points (up to 12 hours) post-dose
|
|
CSF Cmax: Maximum Observed Concentration in Cerebrospinal Fluid (CSF) for TAK-071
Time Frame: Pre-dose on Day 28 and at multiple time points (up to 36 hours) post-dose
|
Pre-dose on Day 28 and at multiple time points (up to 36 hours) post-dose
|
|
CSF AUC(0-12): Area Under the CSF Concentration-time Curve From Time 0 to 12 Hours for TAK-071
Time Frame: Pre-dose on Day 1 and at multiple time points (up to 12 hours) post-dose
|
Pre-dose on Day 1 and at multiple time points (up to 12 hours) post-dose
|
|
CSF AUC(0-36): Area Under the CSF Concentration-time Curve From Time 0 to 36 Hours for TAK-071
Time Frame: Pre-dose on Day 28 and multiple time points (up to 36 hours) post-dose
|
Pre-dose on Day 28 and multiple time points (up to 36 hours) post-dose
|
|
Ratio of CSF AUC(0-12) to the Plasma AUC(0-12) for TAK-071
Time Frame: Pre-dose on Day 1 and at multiple time points [up to 168 hours] post-dose
|
Pre-dose on Day 1 and at multiple time points [up to 168 hours] post-dose
|
|
Ratio of CSF AUC(0-36) to the Plasma AUC(0-36) for TAK-071
Time Frame: Pre-dose on Day 28 and multiple time points (up to 36 hours) post-dose Cohort 9
|
Pre-dose on Day 28 and multiple time points (up to 36 hours) post-dose Cohort 9
|
|
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Donepezil MRD Non-Japanese Participants
Time Frame: Pre-dose on Days -1 and 21 and multiple time points (up to 24 hours) post-dose
|
Pre-dose on Days -1 and 21 and multiple time points (up to 24 hours) post-dose
|
|
Cmax: Maximum Observed Plasma Concentration for Donepezil MRD Non-Japanese Participants
Time Frame: Pre-dose on Days -1 and 21 and multiple time points (up to 24 hours) post-dose
|
Pre-dose on Days -1 and 21 and multiple time points (up to 24 hours) post-dose
|
|
AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Post-dose for Donepezil
Time Frame: Pre-dose on Days -1 and 21 and multiple time points (up to 24 hours) post-dose
|
Pre-dose on Days -1 and 21 and multiple time points (up to 24 hours) post-dose
|
|
Ratio of Geometric Mean of Cmax for Donepezil After 21 Daily Doses of TAK-071
Time Frame: Pre-dose on Days -1 and 21 and multiple time points (up to 24 hours) post-dose
|
A linear mixed effect model on the natural log-transformed parameters was performed with day as a fixed effect and participant as a random effect.
Ratio is the exponentiated geometric mean value Day 21/Day -1 on the original scale.
|
Pre-dose on Days -1 and 21 and multiple time points (up to 24 hours) post-dose
|
Ratio of Geometric Mean of AUC(0-24) for Donepezil After 21 Daily Doses of TAK-071
Time Frame: Pre-dose on Days -1 and 21 and multiple time points (up to 24 hours) post-dose
|
A linear mixed effect model on the natural log-transformed parameters was performed with day as a fixed effect and participant as a random effect.
Ratio is the exponentiated geometric mean value Day 21/Day -1 on the original scale.
|
Pre-dose on Days -1 and 21 and multiple time points (up to 24 hours) post-dose
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurocognitive Disorders
- Neurodegenerative Diseases
- Dementia
- Tauopathies
- Cognition Disorders
- Alzheimer Disease
- Cognitive Dysfunction
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Cholinergic Agents
- Enzyme Inhibitors
- Nootropic Agents
- Cholinesterase Inhibitors
- Donepezil
Other Study ID Numbers
- TAK-071-1001
- U1111-1176-7435 (Registry Identifier: WHO)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer Disease
-
ProgenaBiomeRecruitingAlzheimer Disease | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3 | Alzheimer Disease 4 | Alzheimer Disease 7 | Alzheimer Disease 17 | Alzheimer Disease 5 | Alzheimer Disease 6 | Alzheimer Disease 8 | Alzheimer Disease 10 | Alzheimer... and other conditionsUnited States
-
Cognito Therapeutics, Inc.RecruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | MCI | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Alzheimer Disease 1 | Dementia, Mild | Alzheimer... and other conditionsUnited States
-
AphiosNot yet recruitingDementia | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3
-
Capital Medical UniversityPeking University First Hospital; The First Affiliated Hospital of Anhui Medical... and other collaboratorsRecruitingAlzheimer Disease | Familial Alzheimer Disease (FAD)China
-
University of PennsylvaniaNational Institute on Aging (NIA)CompletedDementia | Alzheimer Disease, At Risk | Alzheimer Disease, Protection AgainstUnited States
-
Kyoto UniversityOsaka University; Mie University; Tokushima University; Tokyo Metropolitan Geriatric... and other collaboratorsCompletedFamilial Alzheimer Disease (FAD) | PSEN1 MutationJapan
-
University of ArizonaNational Institute on Aging (NIA); University of Southern California; Syneos... and other collaboratorsRecruitingNeurodegenerative Diseases | Alzheimer Dementia | Late Onset Alzheimer DiseaseUnited States
-
National Taiwan Normal UniversityCompletedAlzheimer Disease 2 Due to Apoe4 IsoformTaiwan
-
Northwell HealthRecruitingAlzheimer Disease | Alzheimer Disease With Delusions | Alzheimer Disease With PsychosisUnited States
-
University of Kansas Medical CenterNational Institute on Aging (NIA)CompletedHealthy Aging | Alzheimer Disease 2 Due to Apoe4 IsoformUnited States
Clinical Trials on TAK-071 Placebo
-
TakedaMichael J. Fox Foundation for Parkinson's ResearchCompletedParkinson Disease | Healthy ParticipantsUnited States
-
TakedaTerminated
-
Grünenthal GmbHCompletedOsteoarthritis, KneeBelgium
-
TakedaWithdrawn
-
TakedaWithdrawn
-
TakedaTerminatedAttention-Deficit/Hyperactivity DisorderUnited States
-
TakedaTerminatedCardiovascular Disease | Type 2 DiabetesUnited States, France, Poland, Ukraine, Germany, Hong Kong, Taiwan, Argentina, Israel, Mexico, Bulgaria, Malaysia, Romania, Canada, Korea, Republic of, New Zealand, Peru, Estonia, Philippines, Russian Federation, Czech Republic, H... and more